LAVA Therapeutics NV
NASDAQ:LVTX
LAVA Therapeutics NV
NASDAQ:LVTX
Price:
1.16
USD
-1.69%
Market Closed
Market Cap:
30.5m
USD
LAVA Therapeutics NV
EPS (Diluted)
|
LAVA Therapeutics NV
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
EPS (Diluted)
-$1
|
CAGR 3-Years
-37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
EPS (Diluted)
€0
|
CAGR 3-Years
31%
|
CAGR 5-Years
25%
|
CAGR 10-Years
5%
|
|
|
Uniqure NV
NASDAQ:QURE
|
EPS (Diluted)
-$4
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-6%
|
|
|
argenx SE
XBRU:ARGX
|
EPS (Diluted)
$12
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
EPS (Diluted)
-$3
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
LVTX
Intrinsic Value
1.96
USD
Undervaluation 41%
See Also
What is LAVA Therapeutics NV's EPS (Diluted)?
EPS (Diluted)
-1.6
USD
-1.6
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's EPS (Diluted) amounts to -1.6 USD.
What is LAVA Therapeutics NV's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-37%
-37%
Over the last year, the EPS (Diluted) growth was -28%. The average annual EPS (Diluted) growth rates for LAVA Therapeutics NV have been -37% over the past three years .
You don't have any saved screeners yet